Clinical trials: sponsored by Eisai Inc.
Soft Tissue Sarcoma
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
This is a randomized, open-label, multicenter, Phase 3 study comparing the efficacy and safety of eribulin with dacarbazine in subjects with advanced soft tissue sarcoma who have disease progression within 6 months prior to study…
- Trial name
- NCT01327885
- Testing
- Eribulin mesylate 1.4 mg/m^2 intravenous, Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
- Where
- 119 sites in United States, Argentina and 21 more
- Volunteers
- 452 people
- Sponsor
- Eisai Inc.
Solid Tumor or Lymphoma
An Open Label Dose Escalation Study Of E7080
The purpose of this study is to determine the maximum tolerated dose (MTD) of lenvatinib in patients with solid tumors or lymphomas.
- Trial name
- NCT00121719
- Testing
- Lenvatinib
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Myelodysplastic Syndrome
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
The purpose of this study is to determine how the body absorbs decitabine when taken orally in patients with Myelodysplastic Syndrome (MDS). Safety will also be assessed for this oral dose.
- Trial name
- NCT00941109
- Testing
- decitabine
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Eisai Inc.
Colonoscopy, Colon Polyps
A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Elective Colonoscopy
This study was designed to demonstrate that AQUAVAN® is effective in providing adequate sedation in elderly patients undergoing colonoscopy as well as to assess the safety profile of AQUAVAN versus that of midazolam.
- Trial name
- NCT00209599
- Testing
- fospropofol disodium
- Volunteers
- 100 people
- Sponsor
- Eisai Inc.
Obesity
Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects
The purpose of this study is to evaluate the PK properties of lorcaserin in obese or overweight elderly subjects.
- Trial name
- NCT00828581
- Testing
- lorcaserin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Cancer
Dose-Finding Study of E7070 in Combination With Irinotecan
E7070 and irinotecan will be administered to patients with GI tract, pancreatic or lung tumors on Days 1 and 8 of a 21-day cycle, or Days 1 and 15 of a 28-day cycle according to one of two E7070 dose escalation schemes.
- Trial name
- NCT00060567
- Testing
- E7070 + irinotecan combination, Irinotecan + E7070 combination
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Eisai Inc.
Partial Onset Seizures
A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
This is a Non-interventional Prospective Study. Centres will enroll adult patients with partial onset seizures for whom the clinician has decided to initiate ZNS as an adjunctive therapy prior to the decision to take part in this…
- Trial name
- NCT01830868
- Testing
- Zonisamide tablets
- Where
- 37 sites in Austria, Denmark and 3 more
- Volunteers
- 104 people
- Sponsor
- Eisai Inc.
Flexible Bronchoscopy
A Study of AQUAVAN® Injection for Sedation in Elderly Patients Undergoing Flexible Bronchoscopy
This study was designed to demonstrate that AQUAVAN® is effective in providing adequate sedation in patients undergoing flexible bronchoscopy as well as to assess the safety profile of AQUAVAN versus that of midazolam.
- Trial name
- NCT00209586
- Testing
- fospropofol disodium
- Volunteers
- 55 people
- Sponsor
- Eisai Inc.
Healthy Volunteers
A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants
The primary objective of this study is to evaluate the safety and tolerability of single and multiple intravenous infusions of E2814 in healthy adult participants.
- Trial name
- NCT04231513
- Testing
- E2814
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Healthy Volunteers
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
The primary purpose of this study is to demonstrate the bioequivalence (BE) of a single subcutaneous (SC) dose of lecanemab via vial and AI in healthy participants.
- Trial name
- NCT05533801
- Testing
- Lecanemab
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Non Clear Cell Renal Cell Carcinoma (nccRCC)
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
This is a single-arm, multicenter, Phase 2 study of lenvatinib in combination with everolimus in participants with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any…
- Trial name
- NCT02915783
- Testing
- lenvatinib, everolimus
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Eisai Inc.
Solid Tumors
A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors
The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.
- Trial name
- NCT03386942
- Testing
- Farletuzumab Ecteribulin
- Where
- 10 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures
This is an open-label, multicenter study with an Extension Phase to evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to less than [<] 12 years) with…
- Trial name
- NCT02849626
- Testing
- Perampanel
- Where
- 91 sites in United States, Belgium and 10 more
- Volunteers
- 180 people
- Sponsor
- Eisai Inc.
Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of E6201 in subjects with advanced solid tumors.
- Trial name
- NCT00794781
- Testing
- E6201
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- Eisai Inc.
Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
This study will be conducted as an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma…
- Conditions
- Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
- Trial name
- NCT03441360
- Testing
- Eribulin mesylate
- Where
- 41 sites in United States
- Volunteers
- 23 people
- Sponsor
- Eisai Inc.
Glioma
A Study in Subjects With Recurrent Malignant Glioma
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
- Trial name
- NCT01137604
- Testing
- Lenvatinib, Bevacizumab
- Where
- 5 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Eisai Inc.
Lewy Body Disease, Parkinson Disease
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9…
- Trial name
- NCT04764669
- Testing
- E2027
- Where
- 14 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Eisai Inc.
Healthy Volunteers
A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants
The primary objective of this study is to evaluate the safety, tolerability, and plasma pharmacokinetic (PK) of E2511 following multiple oral doses in healthy adult participants.
- Trial name
- NCT05147337
- Testing
- E2511
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Dementia With Lewy Bodies
Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies
This study will be conducted to compare Irsenontrine to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus…
- Trial name
- NCT03467152
- Testing
- Irsenontrine
- Where
- 74 sites in United States, France and 5 more
- Volunteers
- 326 people
- Sponsor
- Eisai Inc.
Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
The Phase 1 part of the study is conducted to determine the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D) of eribulin mesilate in combination with irinotecan hydrochloride in pediatric participants with…
- Conditions
- Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
- Trial name
- NCT03245450
- Testing
- Eribulin mesilate, Irinotecan hydrochloride
- Where
- 39 sites in France, Germany and 6 more
- Volunteers
- 40 people
- Sponsor
- Eisai Inc.